CytomX Therapeutics Inc at JPMorgan Healthcare Conference Transcript
&-
Welcome everyone to the 42nd Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by my squad, [Lorrea Hall], Priyanka Grover, and Malcolm Kuno.
Our next presenting company is CytomX and presenting on behalf of the company, we have CEO, Sean McCarthy. Sean?
Great. Thanks, Anupam. Great to be here. Thanks very much to the JPMorgan team for the invitation to the conference. I will -- in the course of the next 30 minutes or so, I will be making certain forward-looking statements. I refer you to our SEC filings. So today in my presentation, I will review our multi-modality Probody therapeutic pipeline, which is designed to address major unmet needs in oncology. Let me start with a brief company snapshot.
We're a South San Francisco-based clinical-stage oncology-focused company, developing a pipeline centered on our unique and differentiated
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
